Results from an investigator-initiated phase II study performed by researchers at Rigshospitalet using the uTRACE® technology have now been published online ahead of print in the prestigious
The phase II study
The phase II trial (NCT03278275) aimed to evaluate the expression of uPAR in neuroendocrine tumor (NET) patients as well as the prognostic value of uPAR-PET with 68Ga-NOTA-AE105 (uTRACE®). A total of 96 patients of all tumor grades were included and followed for a median of 28 months. The main findings were; 1) the majority, 68%, of all patients and 75% of patients with high grade (NEN G3) tumors had uPAR positive lesions indicating that uPAR as a target for targeted radionuclide therapy may be relevant for the majority of NET patients and notably also for high grade patients, and 2) that uPAR-PET could be used for prognostication both with regard to progression-free survival and overall survival. The authors suggested that "uPAR PET is relevant for risk stratification and uPAR may be a promising target for therapy in patients with NEN".
About neuroendocrine tumors
Each year approximately 35,000 new cases are diagnosed in the US and EU. Due to the long survival of these patients, more than 400,000 patients are living with the disease in the US and EU. Neuroendocrine tumors are a rare form of cancer that occurs in glandular cells most frequently in the lining of the gastrointestinal tract or in the lungs, but the disease can in principle occur in all organs of the body.
About
"We are very excited about the positive data from the phase II study in neuroendocrine tumors patients using the uTRACE® technology that has been published by researcher from Rigshospitalet. Positive results from yet another type of cancer not only underscore that uPAR-PET is a platform technology that can be used across cancer types, but the data also supports the previous findings in other indications. For neuroendocrine tumors the results are particularly exciting as they do not only demonstrate that uTRACE® may be valuable for planning of therapy and follow-up (prognostic value), but since uPAR was demonstrated in the majority of patients it constitutes clinical support for
For more information regarding
Phone: +45 22 83 01 60
E-mail: uk@curasight.com
www.curasight.com
https://news.cision.com/curasight/r/phase-ii-study-of-upar-pet-in-neuroendocrine-tumor-patients-demonstrates-strong-prognostic-value-and,c3493840
https://mb.cision.com/Main/19744/3493840/1526216.pdf
(c) 2022 Cision. All rights reserved., source